Benzodiazepine withdrawal: behavioural pharmacology and neurochemical changes.
This paper describes pharmacological treatments that can reverse the anxiogenic response detected in animal tests when rats are withdrawn from chronic treatment with diazepam. Concurrent treatment with the calcium channel antagonist verapamil prevented this withdrawal response and the benzodiazepine-receptor antagonist flumazenil reversed the anxiogenic response and restored the system to a drug-naive state. Other treatments that reversed the anxiogenic response were the GABAB agonist baclofen, the 5-HT1A receptor agonist buspirone, and the 5-HT3 receptor antagonist (R,S)-zacopride (GABA = gamma-aminobutyric acid; 5-HT = 5-hydroxytryptamine). Both the enantiomers of zacopride contributed to this reversal. These behavioural reversals are interpreted in the light of biochemical studies showing increased 45Ca2+ flux and [3H]5-HT release from the hippocampus, during benzodiazepine withdrawal (Fig. 1).
File
S E
SE
Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital, London, U.K.
Andrews
N
N
D000818:Animals; D014151:Anti-Anxiety Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D001923:Brain Chemistry / Q000187:drug effects*; D006801:Humans; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000378:metabolism* / Q000523:psychology*
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines